Breaking News

Takeda Invests €100M in New Manufacturing Plant

Will support global vaccine strategy and Phase III dengue vaccine candidate

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Takeda Pharmaceutical Co. will invest more than €100 million to build a new manufacturing plant in Singen, Germany for its dengue vaccine candidate. “This manufacturing plant investment reinforces Takeda’s strong support for our global vaccine strategy in general, and dengue in particular. The new plant will provide millions of people with access to a medicine that addresses a huge unmet medical need. It underlines our commitment to improve the lives of people worldwide,” said Dr. Thomas Wozn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters